APA (7th ed.) Citation

NS, S., A, K., A, M., A, M., M, A., L, A., & MH, M. (2025). Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clinical and experimental medicine, 25(1), 238. https://doi.org/10.1007/s10238-025-01751-7

Chicago Style (17th ed.) Citation

NS, Sherafat, Keshavarz A, Mardi A, Mohammadiara A, Aghaei M, Aghebati-Maleki L, and Mohammadi MH. "Rationale of Using Immune Checkpoint Inhibitors (ICIs) and Anti-angiogenic Agents in Cancer Treatment from a Molecular Perspective." Clinical and Experimental Medicine 25, no. 1 (2025): 238. https://doi.org/10.1007/s10238-025-01751-7.

MLA (9th ed.) Citation

NS, Sherafat, et al. "Rationale of Using Immune Checkpoint Inhibitors (ICIs) and Anti-angiogenic Agents in Cancer Treatment from a Molecular Perspective." Clinical and Experimental Medicine, vol. 25, no. 1, 2025, p. 238, https://doi.org/10.1007/s10238-025-01751-7.